Shots:
Health Canada has approved Andembry (garadacimab) for HAE pts (≥12yrs)
Approval was based on P-III (VANGUARD) trial assessing Andembry (n=39) vs PBO (n=25) for 6mos., which showed 62% pts remained attack-free, with reduction in overall HAE attacks by >99% median & 89.2% mean; data was published in The Lancet
Interim analysis of the ongoing OLE…
